NEW YORK (GenomeWeb) – Oxford BioDynamics said today that its subsidiary, Oxford BioDynamics Pte, has signed an exclusive license agreement with Nova Satra Diagnostics Asia (NSDA) under which NSDA will be able to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia using Oxford’s EpiSwitch technology.
Under the terms of the agreement, NSDA will have the right to use the EpiSwitch technology platform and associated reagents for stratification of breast cancer patients. NSDA is solely responsible for completing any required regulatory approval processes and commercialization activities for the breast cancer test within the areas covered by the agreement.
In return, Oxford will receive an upfront licensing payment, royalties on sales of the test, and fees for certain undisclosed milestones, the company said. In Malaysia, Oxford has also agreed to allow NSDA to grant an exclusive sub-license to EpiSwitch to Genting Laboratory Services.
Nova Satra first announced that it was using technology from the University of Oxford to support a blood-based test for breast cancer last month, after receiving a $2 million investment from Genting Bio Cellular.